Evidence map›Paper›PMID 41123748›Full record

ReviewCurrent gastroenterology reports2025

New Kids on the Block: IL-23 Inhibitors in IBD Management.

Jacob Jones, Jeevin Sandhu, Kara Jones, David Dulaney, Anish Patel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current gastroenterology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jacob Jones *Division of Gastroenterology, Brooke Army Medical Center, 3551 Roger Brooke Drive Ft. Sam, Houston, TX, 78234, USA.
Jeevin Sandhu *Department of Medicine, Methodist Dallas Medical Center, Dallas, TX, USA.
Kara Jones *Department of Medicine, Wright Patterson Medical Center, Dayton, OH, USA.
David Dulaney *Division of Gastroenterology, Brooke Army Medical Center, 3551 Roger Brooke Drive Ft. Sam, Houston, TX, 78234, USA.
Anish Patel *Division of Gastroenterology, Brooke Army Medical Center, 3551 Roger Brooke Drive Ft. Sam, Houston, TX, 78234, USA. anishpa81@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewReview the efficacy and safety of IL2319 inhibitors in the management of IBD. RECENT

findingsRisankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.

Indexed as

Antibodies, MonoclonalGastrointestinal AgentsInflammatory Bowel DiseasesInterleukin-23Interleukin-23 Subunit p19Antibodies, Monoclonal, HumanizedHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedGastrointestinal AgentsguselkumabInterleukin-23Interleukin-23 Subunit p19risankizumabBiologic therapyCrohn’s diseaseIL23Inflammatory bowel diseaseP19 inhibitorsUlcerative colitis

Identifiers

PMID41123748

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.